| Literature DB >> 28454852 |
Alba Juan1, Triana Lobatón2, Gustavo Tapia3, Míriam Mañosa4, Eduard Cabré4, Eugeni Domènech4.
Abstract
Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a little known entity that can affect the oropharyngeal mucosa, the gastrointestinal tract and the skin. The main risk factor for the development of this lesion is immunosuppression. Because its features are similar to other Epstein-Barr virus-associated lymphoproliferative disorders, a differential diagnosis can sometimes prove challenging. Here, we report the case of a man diagnosed with Crohn's disease and treated with azathioprine and infliximab who developed ulceration at the rectum that was refractory to conventional medical treatment. Although the histological characteristics were suggestive of an EBVMCU, lymphoproliferative disease could not be ruled out. The patient did not improve after discontinuation of the treatment, a proctectomy was performed and the diagnosis of this disease was confirmed. Although very few cases of EBVMCU affecting the colon have been reported, its diagnosis should be always considered in refractory cases of inflammatory bowel disease with patients undergoing immunosuppressive treatment.Entities:
Keywords: Crohn’s disease; EBV mucocutaneous ulcer; Infliximab
Mesh:
Substances:
Year: 2017 PMID: 28454852 DOI: 10.1016/j.dld.2017.03.011
Source DB: PubMed Journal: Dig Liver Dis ISSN: 1590-8658 Impact factor: 4.088